BTIG analyst Ryan Zimmerman raised the firm’s price target on Stryker (SYK) to $410 from $408 and keeps a Buy rating on the shares. The company delivered solid diversified results in Q3 with revenue of $6.06B, up 10.3% y/y and above/in-line with BTIG/Street estimates as Orthopedics offset some softer spots in MedSurg and Neurotechnology, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Stryker’s Strong Revenue Growth and Margin Expansion Drive Buy Rating
- Stryker’s Strong Q3 2025 Performance and Strategic Initiatives Justify Buy Rating
- Stryker Corp Reports Strong Q3 2025 Results
- Closing Bell Movers: Amazon soars to all-time highs on earnings
- Stryker reports Q3 adjusted EPS $3.19, consensus $3.13